Discovery of internalizing antibodies to basal breast cancer cells. Issue 1 (28th December 2017)

• Record Type: Journal Article
• Authors: Zhou, Yu; Zou, Hao; Yau, Christina; Zhao, Lequn; Hall, Steven C; Drummond, Daryl C; Farr-Jones, Shauna; Park, John W; Benz, Christopher C; Marks, James D
• Is Part Of: Protein engineering, design & selection. Volume 31:Issue 1(2018)
• Page Start: 17
• Page End: 28
• Publication Date: 2017-12-28
• Subjects: basaloid breast cancer -- cancer target discovery -- cell selection -- internalizing single chain Fv antibody -- phage display; Protein engineering -- Periodicals; 660.63
• DOI: 10.1093/protein/gzx063
• Languages: English
• ISSNs: 1741-0126

Abstract

Abstract: We present a strategy to discover recombinant monoclonal antibodies (mAbs) to specific cancers and demonstrate this approach using basal subtype breast cancers. A phage antibody library was depleted of antibodies to common cell surface molecules by incubation with luminal breast cancer cell lines, and then selected on a single basal-like breast cancer cell line (MDA-MB-231) for binding associated receptor-mediated endocytosis. Additional profiling against two luminal and four basal-like cell lines revealed 61 unique basal-specific mAbs from a pool of 1440 phage antibodies. The unique mAbs were further screened on nine basal and seven luminal cell lines to identify those with the greatest affinity, specificity, and internalizing capability for basal-like breast cancer cells. Among the internalizing basal-specific mAbs were those recognizing four transmembrane receptors (EphA2, CD44, CD73 and EGFR), identified by immunoprecipitation–mass spectrometry and yeast-displayed antigen screening. Basal-like breast cancer expression of these four receptors was confirmed using a bioinformatic approach, and expression microarray data on 683 intrinsically subtyped primary breast tumors. This overall approach, which sequentially employs phage display antibody library selection, antigen identification and bioinformatic confirmation of antigen expression by cancer subtypes, offers efficient production of high-affinity mAbs with diagnostic and therapeutic utility against specific cancer subtypes.